Ravulizumab

Pre-clinicalRecruiting

0 views this week 0 watching💤 Quiet

Interest: 33/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myasthenia Gravis, Generalized

Conditions

Myasthenia Gravis, Generalized

Trial Timeline

May 15, 2025 → Dec 31, 2029

NCT ID

NCT06909253

About Ravulizumab

Ravulizumab is a pre-clinical stage product being developed by AstraZeneca for Myasthenia Gravis, Generalized. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06909253. Target conditions include Myasthenia Gravis, Generalized.

What happened to similar drugs?

1 of 20 similar drugs in Myasthenia Gravis, Generalized were approved

Approved (1) Terminated (2) Active (17)

❌SatralizumabChugai PharmaceuticalPhase 3

🔄tacrolimusAstellas PharmaPhase 3

🔄Tacrolimus capsule + PlaceboAstellas PharmaPhase 3

🔄tacrolimus + placeboAstellas PharmaPhase 3

🔄Cladribine Low Dose + Cladribine High DoseMerckPhase 3

🔄Remibrutinib (Blinded) + Remibrutinib (Open Label)NovartisPhase 3

🔄IptacopanNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07399730	Pre-clinical	Recruiting	Apr 1, 2026	Dec 31, 2030	Atypical Hemolytic Uremic Syndrome
NCT06909253	Pre-clinical	Recruiting	May 15, 2025	Dec 31, 2029	Myasthenia Gravis, Generalized
NCT06633536	Pre-clinical	Active	Feb 6, 2025	Aug 1, 2028	Paroxysmal Nocturnal Haemoglobinuria

Competing Products

20 competing products in Myasthenia Gravis, Generalized

See all competitors

Product	Company	Stage	Hype Score
Satralizumab	Chugai Pharmaceutical	Phase 3	32
tacrolimus	Astellas Pharma	Phase 3	40
Tacrolimus capsule + Placebo	Astellas Pharma	Phase 3	40
tacrolimus + placebo	Astellas Pharma	Phase 3	40
Cladribine Low Dose + Cladribine High Dose	Merck	Phase 3	47
Remibrutinib (Blinded) + Remibrutinib (Open Label)	Novartis	Phase 3	47
Placebo + CFZ533	Novartis	Phase 2	35
Iptacopan	Novartis	Phase 3	47
mycophenolate mofetil [CellCept] + Placebo	Roche	Phase 3	40
mycophenolate mofetil (CellCept) + placebo	Roche	Phase 3	40
inebilizumab + IV Placebo	Amgen	Phase 3	44
Inebilizumab	Amgen	Phase 2	42
Abatacept Injection	Bristol Myers Squibb	Phase 1	21
Tolebrutininb + Placebo	Sanofi	Phase 3	32
Pozelimab + Cemdisiran + Cemdisiran + Pozelimab	Regeneron Pharmaceuticals	Phase 3	44
HIZENTRA ®	CSL	Phase 2	35
Subcutaneous immunoglobulins	CSL	Phase 1	21
Human normal immunoglobulin G (IgG)	CSL	Phase 3	40
zilucoplan (RA101495)	UCB	Phase 3	44
zilucoplan (RA101495) + Placebo	UCB	Phase 2	35